At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 26 enrolled
Drug / intervention
CMVIGdrug
Likely dose
CMVIG 400mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Reduction of PRA (Panel Reactive Antibody) in Sensitized Patients Awaiting Live-Donor Renal Transplantation
In Brief
A Phase 4 clinical trial evaluating CMVIG for End Stage Renal Disease. Completed, enrolled 26 participants across 1 site.
Detailed Summary
The purpose of this study is to offer Panel Reactive Antibodies \[PRA\] reduction treatment to high responder renal transplant patients who otherwise may never be compatible with a potential organ donor. PRA reduction is offered in the following phases: 1. Immunological Testing 2. Transplant Nephrectomy 3. Pharmacologic Therapy 4. Plasmapheresis 5. Transplant
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnd Stage Renal Disease
CountriesUnited States
CollaboratorsCSL Behring
Timeline
Phase 4CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2002
First PostedNov 2008
Primary CompletionDec 2010
Study CompletionApr 2012
TodayJul 2026
First PostedNov 5, 2008
Enrollment StartJan 1, 2002
Primary CompletionDec 1, 2010
Study CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8.9 yearsPosted 17.7 years ago
Interventions
CMVIGdrug
400mg/kg IV (60mg/kg/IV/hr initially, titrated up) once a week up to four weeks